NephroPlus Grants 4,01,362 Employee Stock Options at ₹230 Each
Nephrocare Health Services Limited granted 4,01,362 Employee Stock Options under its ESOP 2026. The options are exercisable at ₹230 each and vest after a minimum of one year, subject to conditions. Each option converts to one equity share of face value ₹2.
The grant of employee stock options is a common practice for employee retention and motivation. While it represents potential future dilution, the immediate impact on the company's operations or stock price is typically minimal unless the quantum is exceptionally large or tied to specific performance metrics not detailed here.
The announcement is a routine grant of employee stock options, which is a standard corporate practice and does not inherently indicate a positive or negative change in the company's financial performance or outlook.
Nephrocare Health Services Limited (NEPHROPLUS) announced that its Nomination and Remuneration Committee (NRC) has approved the grant of an aggregate of 4,01,362 Employee Stock Options (Options) under the NephroPlus Employee Stock Option Scheme 2026 (ESOP 2026). These Options were granted on September 3, 2026, to eligible employees identified by the NRC.
Each Option, upon vesting and exercise, will entitle the grantee to acquire one fully paid-up equity share of the Company with a face value of ₹2. The Options have been granted at an exercise price of ₹230 per Option. Vesting is subject to the fulfillment of applicable conditions as specified in the respective Grant Letters, with a minimum vesting period of one year from the Grant Date.
The ESOP 2026 is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The Vested Options may be exercised within a maximum period of 5 years from the date of each respective Vesting, or within a shorter period as prescribed by the NRC. The company has also made this information available on its website.
A plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.